NYSE:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free IKT Stock Alerts $1.71 -0.19 (-10.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.67▼$1.8250-Day Range$1.37▼$2.4752-Week Range$0.79▼$4.35Volume98,983 shsAverage Volume125,254 shsMarket Capitalization$11.08 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Inhibikase Therapeutics alerts: Email Address Inhibikase Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,478.9% Upside$27.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.71) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 starsMedical Sector685th out of 913 stocksBiological Products, Except Diagnostic Industry112th out of 146 stocks 3.5 Analyst's Opinion Consensus RatingInhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IKT. Previous Next 0.0 Dividend Strength Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Inhibikase Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Inhibikase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.81% of the stock of Inhibikase Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Inhibikase Therapeutics Stock (NYSE:IKT)Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Read More IKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKT Stock News HeadlinesApril 26, 2024 | americanbankingnews.comHead to Head Comparison: Inhibikase Therapeutics (NYSE:IKT) versus Kymera Therapeutics (NASDAQ:KYMR)April 22, 2024 | msn.comLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 20, 2024 | investing.comInhibikase Therapeutics progresses in Parkinson's disease trialsApril 19, 2024 | americanbankingnews.comInhibikase Therapeutics (NYSE:IKT) Stock Price Down 1.4%April 18, 2024 | globenewswire.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsApril 3, 2024 | markets.businessinsider.comInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick FactsApril 3, 2024 | globenewswire.comInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory ProgressApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 29, 2024 | finance.yahoo.comQ4 2023 Inhibikase Therapeutics Inc Earnings CallMarch 27, 2024 | globenewswire.comInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityMarch 7, 2024 | finance.yahoo.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 6, 2024 | markets.businessinsider.comBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s PipelineMarch 5, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To KnowFebruary 28, 2024 | globenewswire.comInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProFebruary 21, 2024 | markets.businessinsider.comInhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial StandingFebruary 15, 2024 | finance.yahoo.comHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock NowFebruary 10, 2024 | investing.comInhibikase Therapeutics Inc (IKT)February 8, 2024 | msn.comInhibikase Discusses FDA Pathway for New Cancer DrugFebruary 7, 2024 | msn.comTenax Therapeutics, Equillium among healthcare moversFebruary 7, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersFebruary 6, 2024 | msn.comNew Strong Buy Stocks for February 6thSee More Headlines Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:IKT CUSIPN/A CIK1750149 Webwww.inhibikase.com Phone678-392-3419FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside+1,478.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,030,000.00 Net Margins-5,886.15% Pretax Margin-7,290.80% Return on Equity-107.54% Return on Assets-91.82% Debt Debt-to-Equity RatioN/A Current Ratio4.13 Quick Ratio4.13 Sales & Book Value Annual Sales$260,000.00 Price / Sales42.60 Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.96Miscellaneous Outstanding Shares6,477,000Free Float5,162,000Market Cap$11.08 million OptionableNot Optionable Beta1.19 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Milton H. Werner Ph.D. (Age 60)CEO, President & Director Comp: $697.96kMr. Garth Lees-RolfeChief Financial OfficerDr. Roger RushHead of Preclinical ResearchDr. Surendra SinghHead of Chemistry, Manufacturing & ControlsDr. Charles Warren Olanow B.Sc.F.R.C.P.C., M.D., CEO of Clintrex Research Corporation & Member of Scientific Advisory BoardDan WilliamsControllerMore ExecutivesKey CompetitorsBioCardiaNASDAQ:BCDAOrganovoNASDAQ:ONVOGenetic TechnologiesNASDAQ:GENECoeptis TherapeuticsNASDAQ:COEPSorrento TherapeuticsNASDAQ:SRNEView All Competitors IKT Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibikase Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IKT shares. View IKT analyst ratings or view top-rated stocks. What is Inhibikase Therapeutics' stock price target for 2024? 1 equities research analysts have issued 12-month price targets for Inhibikase Therapeutics' shares. Their IKT share price targets range from $27.00 to $27.00. On average, they anticipate the company's share price to reach $27.00 in the next year. This suggests a possible upside of 1,478.9% from the stock's current price. View analysts price targets for IKT or view top-rated stocks among Wall Street analysts. How have IKT shares performed in 2024? Inhibikase Therapeutics' stock was trading at $1.27 at the beginning of the year. Since then, IKT stock has increased by 34.6% and is now trading at $1.71. View the best growth stocks for 2024 here. When is Inhibikase Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our IKT earnings forecast. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NYSE:IKT) released its earnings results on Wednesday, March, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative trailing twelve-month return on equity of 107.54%. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $15 million in an IPO on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:IKT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
